27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- The FDA has granted Orphan Drug Designation to Aldeyra Therapeutics Inc's (NASDAQ:ALDX) ADX-2191 (methotrexate for intravitreal injection) for primary vitreoretinal lymphoma (PVRL).
- PVRL is a rare ocular lymphoid malignancy consisting of a subset of primary central system lymphoma (PCNSL) and the most common type of intraocular lymphoma.
- ADX-2191 is designed to inhibit dihydrofolate reductase, an enzyme involved in cellular replication and activation.
- Methotrexate is the most commonly used intravitreal medication for the treatment of PVRL.
- Price Action: ALDX shares are up 7.18% at $9.85 during the premarket session on the last check Tuesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!